PFIC1Phase 3PEDFIC 1NCT03566238
This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2
A Phase 3 study testing A4250 (odevixibat) in people with PFIC1 and PFIC2, run by Albireo at 45 sites in 15 countries.
Trial summary
Double blind, randomized, placebo controlled, Phase 3 study to investigate the efficacy and safety of low doses and high doses of A4250 compared to placebo in children with progressive familial intrahepatic cholestasis (PFIC) types 1 and 2. Read more about this study
- Who is it for?
- Ages 6 months to 18 years
- What is being tested?
- A4250 (odevixibat)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 62 participants
- Where
- 45 sitesin 15 countries
- Study dates
- 16 May 2018to 28 Jul 2020
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 months to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- A male or female participant with a clinical diagnosis of PFIC Type 1 or 2 and with a body weight above 5 kg
- Participant must have clinical genetic confirmation of PFIC-1 or PFIC-2
- Participant must have elevated serum bile acid (s-BA) concentration
- Participant must have history of significant pruritus and a caregiver reported observed scratching in the eDiary
- Participant and/or legal guardian must sign informed consent (and assent) as appropriate.
- Participants will be expected to have a consistent caregiver(s) for the duration of the study
- Caregivers and age-appropriate participants (≥8 years of age) must be willing and able to use an eDiary device as required by the study
Who cannot join
- Participant with pathologic variations of the ABCB11 gene that predict complete absence of the bile salt export pump (BSEP) protein
- Participant with past medical history or ongoing presence of other types of liver disease including, but not limited to, the following:
- Biliary atresia of any kind
- Benign recurrent intrahepatic cholestasis, indicated by any history of normal s BAs
- Suspected or proven liver cancer or metastasis to the liver on imaging studies
- Histopathology on liver biopsy that is suggestive of alternate non-PFIC related etiology of cholestasis
Show all 14Show fewer
- Participant with past medical history or ongoing chronic diarrhea
- Any participant with suspected or confirmed cancers except for basal cell carcinoma
- Participant with a past medical history of chronic kidney disease with an impaired renal function and a glomerular filtration rate <70 mL/min/1.73 m^2
- Participant with surgical history of disruption of the enterohepatic circulation (biliary diversion surgery) within 6 months prior to start of Screening Period
- Participant has had a liver transplant or a liver transplant is planned within 6 months of randomization
- Decompensated liver disease
- Participant suffers from uncontrolled, recalcitrant pruritic condition other than PFIC
- Participant who has been previously treated with an IBAT inhibitor whose pruritus has not responded to treatment
Trial locations and contacts
45 sites in 15 countries.
45 sites in 15 countries
United States12 sites
Emory University School of Medicine
Atlanta, Georgia, 30329
Johns Hopkins School of Medicine
Baltimore, Maryland, 21287
Cleveland Clinic
Cleveland, Ohio, 44195
Children's Hospital Colorado
Denver, Colorado, 80045
Baylor College of Medicine - Texas Children's Liver Center
Houston, Texas, 77030
Children's Hospital Los Angeles
Los Angeles, California, 90027
Icahn School of Medicine at Mount Sinai
New York, New York, 10029
Columbia University Medical Center - Presbyterian Hospital Building
New York, New York, 10032
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15224
University of California, San Francisco
San Francisco, California, 94143
Washington University School of Medicine
St Louis, Missouri, 63110
Turkey (Türkiye)5 sites
Gazi University
Ankara
Hacettepe University Faculty of Medicine
Ankara
Akdeniz University
Antalya
Istanbul University Medical Faculty
Istanbul
Inonu University Medical Faculty
Malatya
France4 sites
University and Pediatric Hospital of Lyon
Bron
Universite Paris SUD - Hopitaux Universitaires Paris-Sud - Hopital Bicetre
Le Kremlin-Bicêtre
Hospital de la Timone
Marseille
Hospital Necker-Enfants maladies
Paris
Germany3 sites
Uniklinikum Essen- Kinderklinik II
Essen
Medizinische Hochschule Hannover
Hanover
Kinderklinik Tübingen, Universitätsklinikum Tübingen
Tübingen
Israel3 sites
Rambam Medical Centre
Haifa
Shaare-Zedek Mc
Jerusalem
Schneider Children's Medical Center Of Israel
Petah Tikva
Italy3 sites
Azienda Ospedaliera Papa Giovanni XXIII
Bergamo
University Hospital Of Padova
Padova
Ospedale Regina Margherita
Torino
United Kingdom3 sites
Birmingham Women's and Children's NHS Foundation Trust
Birmingham
Leeds General Infirmary
Leeds
Institute of Liver Studies - Kings College Hospital
London
Belgium2 sites
UZ Leuven
Leuven
Cliniques Universitaires Saint-Luc
Woluwe-Saint-Lambert
Canada2 sites
The Hospital for Sick Children
Toronto
British Columbia Children's Hospital
Vancouver
Netherlands2 sites
University Medical Center Groningen
Groningen
Universitair Medisch Centrum (UMC) Utrecht
Utrecht
Spain2 sites
Hospital Universitari Vall d'Hebron
Barcelona
Hospital Universitario La Paz
Madrid
Saudi Arabia1 site
King Faisal Specialist Hospital & Research Centre
Riyadh, 11211
Sweden1 site
Astrid Lindgren Children's Hospital, Karolinska University Hospital
Solna
About this study
Official title: A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Demonstrate Efficacy and Safety of A4250 in Children With Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 1)
Double blind, randomized, placebo controlled, Phase 3 study to investigate the efficacy and safety of low doses and high doses of A4250 compared to placebo in children with progressive familial intrahepatic cholestasis (PFIC) types 1 and 2.
Read the detailed description
Up to 50 sites in the following countries will take part in this study:
Australia, Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Poland, Spain, Sweden, Turkey, United Kingdom, United States, and Saudi Arabia
- Being tested
- A4250 (odevixibat), Placebo
- Keywords
- Pediatric, Cholestasis
- Medical subject headings
- Cholestasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
A4250 (odevixibat)Drug
A4250 is a small molecule and selective inhibitor of ileal bile acid transporter (IBAT).
PlaceboDrug
Placebo identical in appearance to active drug (A4250).
| Study group | Role | What they receive |
|---|---|---|
| A4250 low dose | Experimental | Capsules for oral administration (40 ug/kg) once daily for 24 weeks Receives: Drug: A4250 (odevixibat) |
| A4250 high dose | Experimental | Capsules for oral administration (120 ug/kg) once daily for 24 weeks Receives: Drug: A4250 (odevixibat) |
| Placebo | Placebo comparator | Capsules for oral administration (to match active) once daily for 24 weeks Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With at Least a 70% Reduction in Fasting Serum Bile Acid (s-BA) Concentration From Baseline to the End of Treatment or Reaching a Level <=70 Micromoles Per Liter (Mcmol/L) After 24 Weeks of Treatment
Fasting s-BA baseline was calculated as the average of the last 2 values prior to the first dose. The end value was the average of the values at Weeks 22 and 24 after the start of double-blind treatment. Participants who had at least 70% reduction in fasting s-BA from baseline to the end of treatment or reached <=70 mcmol/L after 24 weeks of treatment were considered as responder. Participants with missing average at the end of treatment were classified as non-responder. Percentages are rounded to hundredth decimal.
Measured: From Baseline (Day 1) up to Week 24
Percentage of Positive Pruritus Assessments at the Participant Level Based on the Albireo Observer-Reported Outcome (ObsRO) Instrument Over the 24-Week Treatment Period
A positive pruritus assessment was defined as a scratching score of <=1 or at least 1 point drop from baseline. The percentage of positive pruritus assessment was calculated as the number of positive pruritus assessments divided by the total number of reported assessments only when more than 50% of planned assessment recorded by each participant multiplied by 100.
Measured: From Baseline (Day 1) up to Week 24
Secondary outcomes (11)
Change From Baseline in Fasting Serum Bile Acid at Weeks 12 and 24
Blood samples for analysis of s-BA were drawn at all visits. Participants were to fast (water intake only was permissible) for at least 4 hours prior to the collection of samples. Exceptions could be made for infants <12 months of age if they were unable to fast for the full 4 hours. Baseline was the average of the last 2 non-missing values of fasting s-BA concentration prior to the first dose of study treatment.
Measured: Baseline (Day 1) and Weeks 12 and 24
Change From Baseline in Serum Alanine Aminotransferase (ALT) Concentration at Weeks 12 and 24
Blood samples were collected to determine the ALT concentration. Baseline was the last available assessment before the first dose of study treatment.
Measured: Baseline (Day 1) and Weeks 12 and 24
Change From Baseline in Growth Parameters at Weeks 12 and 24
The change in the growth parameters was assessed using linear growth deficit [height (centimeter), weight (kilogram) and body mass index (BMI) (kg/meter square)] compared to standard growth curve (Z-score) calculated by using the software or methods from the centers for disease control (CDC) website for participants with age >=2 years old and from the world health organization website for participants with age <2 years old. Participants whose accurate age was not available, Z-score was not calculated. A Z-score indicated how many standard deviation's (SD) a participant's measurement (like height, weight and BMI), was from the average for their age and sex. A Z-score of 0 represents the median or 50th percentile, while positive or negative values show how far above or below average a measurement was. Baseline was the last available assessment before the first dose of study treatment.
Measured: Baseline (Day 1) and Weeks 12 and 24
Percentage of Responders for Pruritus Assessments Based on Bi-Weekly and Monthly Scores Using the Albireo Observer-Reported Outcome Instrument at Weeks 12 and 24
The responder for pruritus scores was defined as a participant who achieved at least a 1-point reduction in the ObsRO pruritus score. Percentages are rounded to hundredth decimal.
Measured: Weeks 12 and 24
Change From Baseline in Sleep Parameters Based on the Albireo Observer-reported Outcome Instrument Over the 24-Week Treatment Period
The sleep disturbance were recorded twice daily via the electronic diary (eDiary). Participants and/or caregivers completed the eDiary every day in the morning and in the evening. The morning diary was completed shortly after the participant woke up and was used to record nighttime itching and scratching severity, aspects of sleep disturbance, and tiredness upon waking (AM scores). The evening/bedtime diary was completed just before the participant went to bed and recorded participant's itching and scratching severity, and tiredness during the day (PM scores). Both morning and bedtime diaries included Albireo ObsRO and PRO items. Baseline was the average of 14-day scores before the first dose of study treatment.
Measured: Baseline (Day 1) and Weeks 1 to 4, Weeks 5 to 8, Weeks 9 to 12, Weeks 13 to 16, Weeks 17 to 20, and Weeks 21 to 24
Change From Baseline in Sleep Parameters Based on the Albireo Patient-Reported Outcome (PRO) Instrument Over the 24-Week Treatment Period
The ObsRO and electronic diary (eDiary) PRO scale called PRUCISION was used to assess pruritus and sleep outcomes. Participants and/or caregivers completed the eDiary every day in the morning (AM scores) and in the evening (PM scores). Specifically, for difficulty falling or staying asleep, the following 2 respective questions were asked in the Morning Daily eDiary: 1) How hard was it to fall asleep last night because of your itching. and 2) How hard was it to stay asleep last night because of your itching. The PRO was a 5-point scale, and scores ranged from 0 (no itching) to 28 (the worst itching), where higher scores indicated a greater amount of itching, sleep disturbance, and tiredness. No subscales were used. Change in sleep parameters measured with the Albireo PRO and ObsRO instruments by each 4-week interval over the 24-week treatment period was assessed. Baseline was the average of 14-day scores before the first dose of study treatment.
Measured: Baseline (Day 1) and Weeks 1 to 4, Weeks 5 to 8, Weeks 9 to 12, Weeks 13 to 16, Weeks 17 to 20, and Weeks 21 to 24
Percentage of Individual Assessments Meeting the Definition of a Positive Pruritus Assessment at the Participant Level Using the Albireo ObsRO Instrument Over the 24-Week Treatment Period
A positive pruritus assessment was defined as a scratching score of <=1 or at least 1 point drop from baseline based on the Albireo ObsRO instrument. The percentage of positive pruritus assessment was calculated as the number of positive pruritus assessments divided by the total number of reported assessments only when more than 50% of planned assessment recorded by each participant multiplied by 100. At each assessment, the AM or PM score was compared to the baseline AM or PM average, respectively.
Measured: From Baseline (Day 1) up to Week 24
Percentage of Individual Assessments Meeting the Definition of a Positive Pruritus Assessment at the Participant Level Using the Albireo PRO Instrument Over the 24-Week Treatment Period
A positive pruritus assessment was defined as a scratching score of <=1 or at least 1 point drop from baseline based on the Albireo PRO instrument, only participants >=8 years of age completed the Albireo PRO instrument. The percentage of positive pruritus assessment was calculated as the number of positive pruritus assessments divided by the total number of reported assessments only when more than 50% of planned assessment recorded by each participant multiplied by 100. At each assessment, the AM or PM score was compared to the baseline AM or PM average, respectively.
Measured: From Baseline (Day 1) up to Week 24
Percentage of Individual Assessments Meeting the Definition of a Positive Pruritus Assessment at the Participant Level Using the Albireo ObsRO Instrument Over the 24-Week Treatment Period
A positive pruritus assessment was defined as a scratching score of <=1 or at least 1 point drop from baseline based on the Albireo ObsRO instrument. The percentage of positive pruritus assessment was calculated as the number of positive pruritus assessments divided by the total number of reported assessments only when more than 50% of planned assessment recorded by each participant multiplied by 100. At each assessment, the AM or PM score was compared to the baseline AM or PM average, respectively.
Measured: Baseline (Day 1) and Weeks 1 to 4, Weeks 5 to 8, Weeks 9 to 12, Weeks 13 to 16, Weeks 17 to 20, and Weeks 21 to 24
Number of Participants Underwent Biliary Diversion Surgery and Liver Transplantation
The number of participants underwent biliary diversion surgery and liver transplantation was determined.
Measured: From Baseline (Day 1) up to Week 24
Number of Participants Achieved Positive Pruritus Assessment for >50% of the Time Based on the Albireo ObsRO and PRO Instruments Over the 24-Week Treatment Period
A positive pruritus assessment was defined as a scratching score of <=1 or at least 1 point drop from baseline based on the Albireo ObsRO and PRO instruments. The percentage of positive pruritus assessment was calculated as the number of positive pruritus assessments divided by the total number of reported assessments only when more than 50% of planned assessment recorded by each participant multiplied by 100.
Measured: From Baseline (Day 1) up to Week 24
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jun 2018
- Study start16 May 2018
- Primary completion27 Jul 2020
- Study completion28 Jul 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for PFIC1Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Double-Blind, Randomized, Placebo-Controlled
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 62 participants (actual)
Sponsor and investigators
- Lead sponsor
- Albireo
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03566238
- Sponsor's protocol ID
- A4250-005
- Acronym
- PEDFIC 1
- Status last verified
- Nov 2025
- First submitted
- 25 May 2018
- Last updated
- 28 Nov 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Publications
Gwaltney C, Ivanescu C, Karlsson L, Warholic N, Kjems L, Horn P. Validation of the PRUCISION Instruments in Pediatric Patients with Progressive Familial Intrahepatic Cholestasis. Adv Ther. 2022 Nov;39(11):5105-5125. doi: 10.1007/s12325-022-02262-7. Epub 2022 Sep 6.
PubMed 36066745Thompson RJ, Arnell H, Artan R, Baumann U, Calvo PL, Czubkowski P, Dalgic B, D'Antiga L, Durmaz O, Fischler B, Gonzales E, Grammatikopoulos T, Gupte G, Hardikar W, Houwen RHJ, Kamath BM, Karpen SJ, Kjems L, Lacaille F, Lachaux A, Lainka E, Mack CL, Mattsson JP, McKiernan P, Ozen H, Rajwal SR, Roquelaure B, Shagrani M, Shteyer E, Soufi N, Sturm E, Tessier ME, Verkade HJ, Horn P. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2022 Sep;7(9):830-842. doi: 10.1016/S2468-1253(22)00093-0. Epub 2022 Jul 1.
PubMed 35780807
Study at a glance
From the registry record, last updated by the sponsor on 28 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Demonstrate Efficacy and Safety of A4250 in Children With Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 1)
- ClinicalTrials.gov ID
- NCT03566238
- Acronym / sponsor ID
- PEDFIC 1 / A4250-005
- Keywords
- Pediatric, Cholestasis
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 62 participants (actual)
- Lead sponsor
- AlbireoIndustry (pharma, biotech, devices)
- Study start
- 16 May 2018 (actual)
- Primary completion
- 27 Jul 2020 (actual)
- Study completion
- 28 Jul 2020 (actual)
- First posted
- 25 Jun 2018 (actual)
- Results
- Posted 5 Sep 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Double blind, randomized, placebo controlled, Phase 3 study to investigate the efficacy and safety of low doses and high doses of A4250 compared to placebo in children with progressive familial intrahepatic cholestasis (PFIC) types 1 and 2.
Detailed description
Up to 50 sites in the following countries will take part in this study:
Australia, Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Poland, Spain, Sweden, Turkey, United Kingdom, United States, and Saudi Arabia
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
- Model description
- Double-Blind, Randomized, Placebo-Controlled
| Arm | Type | Receives |
|---|---|---|
| A4250 low dose | Experimental | Drug: A4250 (odevixibat)Capsules for oral administration (40 ug/kg) once daily for 24 weeks |
| A4250 high dose | Experimental | Drug: A4250 (odevixibat)Capsules for oral administration (120 ug/kg) once daily for 24 weeks |
| Placebo | Placebo comparator | Drug: PlaceboCapsules for oral administration (to match active) once daily for 24 weeks |
Who may qualify
- Ages
- 6 months to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (7 listed)
- A male or female participant with a clinical diagnosis of PFIC Type 1 or 2 and with a body weight above 5 kg
- Participant must have clinical genetic confirmation of PFIC-1 or PFIC-2
- Participant must have elevated serum bile acid (s-BA) concentration
- Participant must have history of significant pruritus and a caregiver reported observed scratching in the eDiary
- Participant and/or legal guardian must sign informed consent (and assent) as appropriate.
Key exclusion criteria (14 listed)
- Participant with pathologic variations of the ABCB11 gene that predict complete absence of the bile salt export pump (BSEP) protein
- Participant with past medical history or ongoing presence of other types of liver disease including, but not limited to, the following:
- Participant with past medical history or ongoing chronic diarrhea
- Any participant with suspected or confirmed cancers except for basal cell carcinoma
- Participant with a past medical history of chronic kidney disease with an impaired renal function and a glomerular filtration rate <70 mL/min/1.73 m^2
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| A4250 (odevixibat)A4250 is a small molecule and selective inhibitor of ileal bile acid transporter (IBAT). | Drug | A4250 high dose, A4250 low dose |
| PlaceboPlacebo identical in appearance to active drug (A4250). | Drug | Placebo |
Primary outcome
Percentage of Participants With at Least a 70% Reduction in Fasting Serum Bile Acid (s-BA) Concentration From Baseline to the End of Treatment or Reaching a Level <=70 Micromoles Per Liter (Mcmol/L) After 24 Weeks of Treatment
Time frame: From Baseline (Day 1) up to Week 24
Fasting s-BA baseline was calculated as the average of the last 2 values prior to the first dose. The end value was the average of the values at Weeks 22 and 24 after the start of double-blind treatment. Participants who had at least 70% reduction in fasting s-BA from baseline to the end of treatment or reached <=70 mcmol/L after 24 weeks of treatment were considered as responder. Participants with missing average at the end of treatment were classified as non-responder. Percentages are rounded to hundredth decimal.
Percentage of Positive Pruritus Assessments at the Participant Level Based on the Albireo Observer-Reported Outcome (ObsRO) Instrument Over the 24-Week Treatment Period
Time frame: From Baseline (Day 1) up to Week 24
A positive pruritus assessment was defined as a scratching score of <=1 or at least 1 point drop from baseline. The percentage of positive pruritus assessment was calculated as the number of positive pruritus assessments divided by the total number of reported assessments only when more than 50% of planned assessment recorded by each participant multiplied by 100.
11 secondary outcomes
Change From Baseline in Fasting Serum Bile Acid at Weeks 12 and 24
Time frame: Baseline (Day 1) and Weeks 12 and 24
Change From Baseline in Serum Alanine Aminotransferase (ALT) Concentration at Weeks 12 and 24
Time frame: Baseline (Day 1) and Weeks 12 and 24
Change From Baseline in Growth Parameters at Weeks 12 and 24
Time frame: Baseline (Day 1) and Weeks 12 and 24
Percentage of Responders for Pruritus Assessments Based on Bi-Weekly and Monthly Scores Using the Albireo Observer-Reported Outcome Instrument at Weeks 12 and 24
Time frame: Weeks 12 and 24
Change From Baseline in Sleep Parameters Based on the Albireo Observer-reported Outcome Instrument Over the 24-Week Treatment Period
Time frame: Baseline (Day 1) and Weeks 1 to 4, Weeks 5 to 8, Weeks 9 to 12, Weeks 13 to 16, Weeks 17 to 20, and Weeks 21 to 24
Change From Baseline in Sleep Parameters Based on the Albireo Patient-Reported Outcome (PRO) Instrument Over the 24-Week Treatment Period
Time frame: Baseline (Day 1) and Weeks 1 to 4, Weeks 5 to 8, Weeks 9 to 12, Weeks 13 to 16, Weeks 17 to 20, and Weeks 21 to 24
Percentage of Individual Assessments Meeting the Definition of a Positive Pruritus Assessment at the Participant Level Using the Albireo ObsRO Instrument Over the 24-Week Treatment Period
Time frame: From Baseline (Day 1) up to Week 24
Percentage of Individual Assessments Meeting the Definition of a Positive Pruritus Assessment at the Participant Level Using the Albireo PRO Instrument Over the 24-Week Treatment Period
Time frame: From Baseline (Day 1) up to Week 24
Percentage of Individual Assessments Meeting the Definition of a Positive Pruritus Assessment at the Participant Level Using the Albireo ObsRO Instrument Over the 24-Week Treatment Period
Time frame: Baseline (Day 1) and Weeks 1 to 4, Weeks 5 to 8, Weeks 9 to 12, Weeks 13 to 16, Weeks 17 to 20, and Weeks 21 to 24
Number of Participants Underwent Biliary Diversion Surgery and Liver Transplantation
Time frame: From Baseline (Day 1) up to Week 24
Number of Participants Achieved Positive Pruritus Assessment for >50% of the Time Based on the Albireo ObsRO and PRO Instruments Over the 24-Week Treatment Period
Time frame: From Baseline (Day 1) up to Week 24
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Nov 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 36066745Gwaltney C, Ivanescu C, Karlsson L, Warholic N, Kjems L, Horn P. Validation of the PRUCISION Instruments in Pediatric Patients with Progressive Familial Intrahepatic Cholestasis. Adv Ther. 2022 Nov;39(11):5105-5125. doi: 10.1007/s12325-022-02262-7. Epub 2022 Sep 6.
- Derived from this study: PubMed 35780807Thompson RJ, Arnell H, Artan R, Baumann U, Calvo PL, Czubkowski P, Dalgic B, D'Antiga L, Durmaz O, Fischler B, Gonzales E, Grammatikopoulos T, Gupte G, Hardikar W, Houwen RHJ, Kamath BM, Karpen SJ, Kjems L, Lacaille F, Lachaux A, Lainka E, Mack CL, Mattsson JP, McKiernan P, Ozen H, Rajwal SR, Roquelaure B, Shagrani M, Shteyer E, Soufi N, Sturm E, Tessier ME, Verkade HJ, Horn P. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2022 Sep;7(9):830-842. doi: 10.1016/S2468-1253(22)00093-0. Epub 2022 Jul 1.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
45 sites in 15 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing A4250 (odevixibat) in people with PFIC1 and PFIC2, run by Albireo at 45 sites in 15 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 45 sites in United States, Turkey (Türkiye), France, Germany, Israel and 10 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 5 Sep 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants With at Least a 70% Reduction in Fasting Serum Bile Acid (s-BA) Concentration From Baseline to the End of Treatment or Reaching a Level <=70 Micromoles Per Liter (Mcmol/L) After 24 Weeks of Treatment (time frame: From Baseline (Day 1) up to Week 24). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03566238, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Nov 2025; AzTrials last refreshed its copy on 7 Nov 2026.